Cargando…

Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes

BACKGROUND: The aim of this prospective open-label single-arm single-center follow-up study was to analyze glycemic control in children and adolescents with type 1 diabetes treated with the advanced hybrid closed loop (AHCL) system in relation to a sensor-augmented pump with low-glucose suspend (SAP...

Descripción completa

Detalles Bibliográficos
Autores principales: Seget, Sebastian, Rusak, Ewa, Polanska, Joanna, Jarosz-Chobot, Przemysława
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618370/
https://www.ncbi.nlm.nih.gov/pubmed/35852811
http://dx.doi.org/10.1089/dia.2022.0148
_version_ 1784821034282647552
author Seget, Sebastian
Rusak, Ewa
Polanska, Joanna
Jarosz-Chobot, Przemysława
author_facet Seget, Sebastian
Rusak, Ewa
Polanska, Joanna
Jarosz-Chobot, Przemysława
author_sort Seget, Sebastian
collection PubMed
description BACKGROUND: The aim of this prospective open-label single-arm single-center follow-up study was to analyze glycemic control in children and adolescents with type 1 diabetes treated with the advanced hybrid closed loop (AHCL) system in relation to a sensor-augmented pump with low-glucose suspend (SAP-LGS) or predictive low-glucose suspend (SAP-PLGS). MATERIALS AND METHODS: The data for 50 children and adolescents (age 5.5–19.6 years) with type 1 diabetes, receiving insulin through an AHCL system after being switched from SAP-LGS/PLGS systems, were included in the analysis. The SAP-LGS/PLGS records from 2 weeks preceding the AHCL connection were compared with the records from the first 4 weeks of AHCL use, represented as two separate 2-week intervals. RESULTS: Significant improvements in most of the parameters, namely time spent in the range of 70–140 mg/dL (from 53.80% ± 12.35% to 61.70% ± 8.42%, P < 0.001) and 70–180 mg/dL (from 76.17% ± 10.28% to 81.32% ± 7.71%, P < 0.001), average sensor glucose (from 138.61 ± 16.66 to 130.02 ± 10.91 mg/dL, P < 0.001), and glucose management indicator (from 6.54% ± 0.45% to 6.27% ± 0.29%, P = 0.001), were observed within 2 weeks of switching to the AHCL. More evident improvements were observed for the parameters monitored at night than during the day. The potential limitations of this study were the short observation time, lack of glycated hemoglobin measurements, and no control arm. CONCLUSION: The AHCL system can significantly improve glycemic control even in well-controlled children and adolescents with type 1 diabetes by increasing the proportion of time spent in the narrower range of 70–140 mg/dL and decreasing the mean glucose concentration, especially during the night.
format Online
Article
Text
id pubmed-9618370
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-96183702022-10-31 Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes Seget, Sebastian Rusak, Ewa Polanska, Joanna Jarosz-Chobot, Przemysława Diabetes Technol Ther Original Articles BACKGROUND: The aim of this prospective open-label single-arm single-center follow-up study was to analyze glycemic control in children and adolescents with type 1 diabetes treated with the advanced hybrid closed loop (AHCL) system in relation to a sensor-augmented pump with low-glucose suspend (SAP-LGS) or predictive low-glucose suspend (SAP-PLGS). MATERIALS AND METHODS: The data for 50 children and adolescents (age 5.5–19.6 years) with type 1 diabetes, receiving insulin through an AHCL system after being switched from SAP-LGS/PLGS systems, were included in the analysis. The SAP-LGS/PLGS records from 2 weeks preceding the AHCL connection were compared with the records from the first 4 weeks of AHCL use, represented as two separate 2-week intervals. RESULTS: Significant improvements in most of the parameters, namely time spent in the range of 70–140 mg/dL (from 53.80% ± 12.35% to 61.70% ± 8.42%, P < 0.001) and 70–180 mg/dL (from 76.17% ± 10.28% to 81.32% ± 7.71%, P < 0.001), average sensor glucose (from 138.61 ± 16.66 to 130.02 ± 10.91 mg/dL, P < 0.001), and glucose management indicator (from 6.54% ± 0.45% to 6.27% ± 0.29%, P = 0.001), were observed within 2 weeks of switching to the AHCL. More evident improvements were observed for the parameters monitored at night than during the day. The potential limitations of this study were the short observation time, lack of glycated hemoglobin measurements, and no control arm. CONCLUSION: The AHCL system can significantly improve glycemic control even in well-controlled children and adolescents with type 1 diabetes by increasing the proportion of time spent in the narrower range of 70–140 mg/dL and decreasing the mean glucose concentration, especially during the night. Mary Ann Liebert, Inc., publishers 2022-11-01 2022-10-31 /pmc/articles/PMC9618370/ /pubmed/35852811 http://dx.doi.org/10.1089/dia.2022.0148 Text en © Sebastian Seget, et al., 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by-nc/4.0/This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Articles
Seget, Sebastian
Rusak, Ewa
Polanska, Joanna
Jarosz-Chobot, Przemysława
Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes
title Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes
title_full Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes
title_fullStr Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes
title_full_unstemmed Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes
title_short Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes
title_sort prospective open-label, single-arm, single-center follow-up study of the application of the advanced hybrid closed loop system in well-controlled children and adolescents with type 1 diabetes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618370/
https://www.ncbi.nlm.nih.gov/pubmed/35852811
http://dx.doi.org/10.1089/dia.2022.0148
work_keys_str_mv AT segetsebastian prospectiveopenlabelsinglearmsinglecenterfollowupstudyoftheapplicationoftheadvancedhybridclosedloopsysteminwellcontrolledchildrenandadolescentswithtype1diabetes
AT rusakewa prospectiveopenlabelsinglearmsinglecenterfollowupstudyoftheapplicationoftheadvancedhybridclosedloopsysteminwellcontrolledchildrenandadolescentswithtype1diabetes
AT polanskajoanna prospectiveopenlabelsinglearmsinglecenterfollowupstudyoftheapplicationoftheadvancedhybridclosedloopsysteminwellcontrolledchildrenandadolescentswithtype1diabetes
AT jaroszchobotprzemysława prospectiveopenlabelsinglearmsinglecenterfollowupstudyoftheapplicationoftheadvancedhybridclosedloopsysteminwellcontrolledchildrenandadolescentswithtype1diabetes